Neovacs S.A. Price Chart
Neovacs S.A. 0LW.F Financial and Trading Overview
| Neovacs S.A. stock price | 0.0005 EUR |
| Previous Close | 0.73 EUR |
| Open | 0.71 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0.7 - 0.72 EUR |
| 52 Week Range | 0.67 - 2688 EUR |
| Volume | 349 EUR |
| Avg. Volume | 153 EUR |
| Market Cap | N/A |
| Beta (5Y Monthly) | -0.013152 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0LW.F Valuation Measures
| Enterprise Value | 181.3M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.4326923 |
| Enterprise Value/Revenue | 163040.17 |
| Enterprise Value/EBITDA | -28.807 |
Trading Information
Neovacs S.A. Stock Price History
| Beta (5Y Monthly) | -0.013152 |
| 52-Week Change | -99.93% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2688 EUR |
| 52 Week Low | 0.67 EUR |
| 50-Day Moving Average | 1.45 EUR |
| 200-Day Moving Average | 85.41 EUR |
0LW.F Share Statistics
| Avg. Volume (3 month) | 153 EUR |
| Avg. Daily Volume (10-Days) | 557 EUR |
| Shares Outstanding | N/A |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1.25E-4:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -579583.25% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -7.75% |
| Return on Equity (ttm) | -7.54% |
Income Statement
| Revenue (ttm) | 1.11K EUR |
| Revenue Per Share (ttm) | 0 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -3392605 EUR |
| EBITDA | -6293671 EUR |
| Net Income Avi to Common (ttm) | -3548503 EUR |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.76M EUR |
| Total Cash Per Share (mrq) | 0.03 EUR |
| Total Debt (mrq) | 1.2M EUR |
| Total Debt/Equity (mrq) | 2.4 EUR |
| Current Ratio (mrq) | 2.682 |
| Book Value Per Share (mrq) | 0.208 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4448512 EUR |
| Levered Free Cash Flow (ttm) | -3495808 EUR |
Profile of Neovacs S.A.
| Country | Germany |
| State | N/A |
| City | Paris |
| Address | 3-5, Impasse Reille |
| ZIP | 75014 |
| Phone | N/A |
| Website | https://www.neovacs.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 21 |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
Q&A For Neovacs S.A. Stock
What is a current 0LW.F stock price?
Neovacs S.A. 0LW.F stock price today per share is 0.0005 EUR.
How to purchase Neovacs S.A. stock?
You can buy 0LW.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neovacs S.A.?
The stock symbol or ticker of Neovacs S.A. is 0LW.F.
How many shares does Neovacs S.A. have in circulation?
The max supply of Neovacs S.A. shares is 0.
What is Neovacs S.A. Price to Earnings Ratio (PE Ratio)?
Neovacs S.A. PE Ratio is 0.00000000 now.
What was Neovacs S.A. earnings per share over the trailing 12 months (TTM)?
Neovacs S.A. EPS is 0 EUR over the trailing 12 months.